Document registry — page 40
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low04 Jun 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over 48 weeks. Primary result: An adjunctive effect in combination…
Moderate03 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Jun 2023 -
Confirmation of peptide identity by liquid chromatography–tandem mass spectrometry
High02 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low02 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Larazotide acetate in mucosal barrier over 12 weeks. Primary result: Terminated at a pre-planned interim…
01 Jun 2023 -
Randomised crossover, phase 1 study of Semaglutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low01 Jun 2023 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low01 Jun 2023 -
Randomised crossover, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low30 May 2023 -
Phase 1 ascending dose, phase 1 study of GHRP-6 in gh axis over single dose. Primary result: Dose-dependent growth-hormone release with a marked orexigenic effect.
Low29 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low29 May 2023 -
Observational, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low28 May 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low28 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low26 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Pramlintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low25 May 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes randomising 3,183 participants over median 15.9…
High24 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low23 May 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low21 May 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 May 2023 -
Triple GIP, GLP-1 and glucagon receptor agonist (acylated). Retatrutide adds glucagon receptor agonism to the dual incretin mechanism. Glucagon receptor activation increases hepatic fatty-acid oxidation and…
Moderate19 May 2023 -
Randomised crossover, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low16 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low13 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) randomising 1,398 participants over 52 weeks. Primary result…
Moderate10 May 2023 -
Single-arm open-label, phase 1 study of Hexarelin in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low10 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Retatrutide in obesity randomising 338 participants over 48 weeks. Primary result: Mean change −24.2 % at…
Moderate09 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes randomising 680 participants over 24 weeks. Primary result: Reduction of…
High09 May 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over single dose. Primary result: Marked growth-hormone release with attenuation on repeated administration.
Low09 May 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of LL-37 in wound healing over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 May 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 May 2023 -
Phase 1 ascending dose, phase 1 study of Ipamorelin in gh axis over single dose. Primary result: Dose-dependent growth-hormone release without a measurable rise in…
Low05 May 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 May 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low05 May 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported…
Very low05 May 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 1,098 participants over 52 weeks. Primary result: Superior to…
High04 May 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 May 2023
page 40 of 41